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eligible. Direct sequencing using DNA extracted from parafﬁn-embed-
ded tumor specimens to detect mutations in EGFR (exons 18, 19 and 
21) was performed in a central laboratory, and the median time for 
the analysis required 12 days (range 7-28). The primary objective was 
the objective response rate of geﬁtinib in NSCLC patients with EGFR 
mutations. With the target activity level of 50% and the lowest response 
rate of interest set at 25%, 23 eligible patients were required to accept 
the hypothesis. 
Results: Between March 2005 and January 2006, EGFR mutations 
were detected in 32 patients (27%) in 118 screened NSCLC patients. 
EGFR mutations were signiﬁcantly frequent in females, in adenocar-
cinoma histology and never smoker. Twenty-eight of the 32 patients 
have been enrolled onto this study; 14 patients had deletional mutations 
in exon 19 and 14 patients had missense mutations in exon 21. Of the 
28 patients with EGFR mutations: adenocarcinoma (27), female (18) 
and never smoker (19). Overall response rate was 77.8 % and disease 
control rate was 100% ( 1 CR, 20 PR, 6 SD, 1 NE and no PD ). The 
median PFS time was 10.8 months (95% Cl. 7.3 months to -). The 
median OS has not yet been reached, and 1Y-S was 80%. In the subset 
analysis of PFS, there was no signiﬁcant difference between sex (male 
vs. female), PS (PS0/1 vs. PS2), number of prior regimens (0 vs. 1/2) 
and the site of EGFR mutations (exon 19 vs. exon 21). 1Y-S of exon 19 
was 92.9% and exon 21 was 68.8%. There was no signiﬁcant differ-
ence. The most common toxicities (grade 2-4) were rash observed in 
13 (46%) patients, dry skin in 10(36%) patients and elevated AST/ALT 
in 6(21%) patients. Interstitial lung disease was occurred in 3(11%) pa-
tients (2pts:Grade1, 1pt:Grade4). There was no treatment related death. 
Conclusions: These data prospectively veriﬁed the validity of EGFR 
mutations as an important predictor of geﬁtinib responsiveness. A mul-
ticenter phase II with patient’s selection by central EGFR gene review 
has successfully done.
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Introduction: CT is the standard of care for patients with metastatic 
NSCLC. The use of EGFR inhibitors has an emerging role in this dis-
ease but it is not clear the potential beneﬁt of adding these drugs in the 
ﬁrst line setting. This meta-analysis aims to quantify the treatment ef-
fect of EGFR inhibitors plus standard CT in the treatment of advanced 
NSCLC and compare the combination to standard CT.
Purpose: analyze the efﬁcacy and safety of the addition of EGFR-
TKIs, Geﬁtinib or Erlotinib and Cetuximab to the standard chemothera-
py in chemo-naïve patients with advanced NSCLC.
Patients and methods: We have made an extensive search in the 
PubMed, looking for randomized trials (RT) in untreated patients with 
locally advanced or metastatic NSCLC, that compare standard platinum 
based chemotherapy with or without anti -EGFR agents. We found ﬁve 
RT that matched with our search criteria: four RT compare EGFR-TKIs 
with chemotherapy versus standard chemotherapy, and one Phase II 
RT that explored the addition of Cetuximab in the ﬁrst line setting. We 
used the Mantel-Haenszel method to calculate the weighted summary 
Odds ratio (OR) under the ﬁxed and random effects model.
Results: Data from a total of 3632 patients from 5 randomized trials 
were included. 
 
EGFR 
inhibitor+CT
Chemotherapy OR (95% CI) P value
ORR 584/1814 pts 546/1820 pts 1.11 (0.92-1.23) NS
1-year OS 764/1771 pts 754/1777 pts 1.03 (0.90-1.18) NS
Overall Surv. 1292/1812 pts 1293/1820 pts 1.01 (0.87-1.17) NS
Rash Gr 3/4 354/1406 pts 283/1416 pts 1.44 (1.19-1.75) <0.001
Diarrhea Gr 3/4 110/1236 pts 24/1241 pts 3.93 (2.09-5.22 <0.001
 
No differences were found in all the efﬁcacy endpoints evaluated, 
including overall survival, 1 year survival, overall response. Regard-
ing toxicity there was a signiﬁcant increase in rash and diarrhea. No 
signiﬁcant difference were observed neither in the incidence of lung 
interstitial disease nor in other safety parameters.
Conclusions: The combination of standard chemotherapy with EGFR 
inhibitors did not neither improve survival, progression free survival, 
nor response rate compared with chemotherapy given alone. These 
results conﬁrm the lack of beneﬁt of this strategy in unselected patient 
population. Further investigations are required to identify potential sub-
group of patients who could beneﬁt with the addition of these agents 
including sequential strategies.
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Background: The optimal strategy in advanced NSCLC with stable 
disease is not well known. The sequence and the drugs are not deﬁned.
Purpose: To evaluate the efﬁcacy and safety of early modiﬁcation of 
chemotherapy doublets in patients with advanced non small cell lung 
cancer with stable disease (SD).
Methods: Patients with stage IV NSCLC and measurable disease were 
included in a randomized phase II trial comparing for patients with 
stable disease after 2 cycles of a platin (P)-gemcitabine doublet (P d1: 
75 mg/m2, gemcitabine 1 250 mg/m2 d1, d8 every three weeks) two 
subsequent cycles of this doublet (arm A) to a switch to another doublet 
(arm B): paclitaxel 100 mg/m2 d1, d8, d15, gemcitabine 1 250 mg/m2 
d1, d8, every four weeks. 
Results: Between October 2003 and august 2006, 228 patients (pts) 
were enrolled (187 males, 41 females), median age 57 y (30-70). 
Evaluation (EVA) 1 showed 98 patients (43%) with stable diseases (87 
patients were randomized). 48.3% were PS0, 51.7% PS1; 41.4% had 
only one metastatic site. Efﬁcacy at eva 2 is depicted above. Overall 
survival (OS) was similar between the two arms: 9.8 months (m) [7.0 
